Key Facts · 2026-09-14
- The Ordinary launched in 2016 under DECIEM and became one of the fastest-growing skincare brands of the decade.
- Estée Lauder acquired DECIEM in full for about $1 billion (completed 2024) after buying in incrementally from 2017.
- Its model: name the active (e.g., 'Niacinamide 10% + Zinc 1%') and price near cost — radical transparency.
- Lesson: a competent OEM can deliver clinical-style formulas at accessible price points if the brief is clear.
2016
Launch
~$1B
DECIEM exit
10%+
Niacinamide hero
透明定价
Moat
The anti-beauty-beauty brand
The Ordinary stripped skincare down to the active ingredient and the price. Instead of poetic marketing, bottles said 'Granactive Retinoid 2%' and cost a few dollars. That honesty became the brand, and it scaled globally through word-of-mouth and a devoted Reddit/YouTube following.
Why the model was manufacturable
- Simple, repeatable formulas are easier and cheaper to produce consistently at scale.
- Clear briefs ('deliver X% active, stable, elegant') let the manufacturer optimise cost without guesswork.
- Small pack sizes lowered trial cost for consumers and inventory risk for the brand.
The Ordinary proved that 'clinical' and 'affordable' are not opposites when the supply chain is disciplined.
Private-label lessons
- Lead with a clear, defensible claim (the active + the proof), not vague benefit language.
- Write a precise formulation brief so your OEM can hit both efficacy and cost.
- Use accessible price points to drive trial; scale on repurchase, not one-off hype.
- Build trust through education (what the ingredient does, how to use it) — it compounds.
The cautionary side
Transparency invites scrutiny: every formula claim must be substantiated and compliant (see the Compliance Guide). The Ordinary's parent also faced operational turbulence — a reminder that brand hype needs a solid manufacturing and quality backbone.
Frequently Asked Questions
Who owns The Ordinary?
The Ordinary is part of DECIEM, which Estée Lauder acquired in full for about $1 billion, completed in 2024.
What made The Ordinary successful?
Radical ingredient transparency and near-cost pricing, backed by simple, repeatable formulas a competent OEM could produce at scale.
What can a private-label brand copy?
A clear active-led claim, a precise formulation brief, and education-led trust — while keeping every claim compliant.
Launch a transparent, affordable line
Brief a capable OEM on active-led formulas at accessible price points — free match.
Get a formulation match